Erlotinib/Gemcitabine for First-Line Treatment of Locally Advanced or Metastatic Adenocarcinoma of the Pancreas
作者： Justice R , Johnson , Pazdur R , Sridhara R , Senderowicz Am
DOI:
关键词: Internal medicine 、 Oncology 、 Tyrosine-kinase inhibitor 、 Chemotherapy regimen 、 Medicine 、 Pancreas 、 Epidermal growth factor receptor 、 Lung cancer 、 Erlotinib 、 Pancreatic cancer 、 Gemcitabine
摘要: Erlotinib (Tarceva) is a human epidermal growth factor receptor type 1/epidermal (HER1/EGFR) tyrosine kinase inhibitor initially approved by the US Food and Drug Administration for treatment of patients with locally advanced or metastatic non–small-cell lung cancer after failure at least one prior chemotherapy regimen. In this report, we present pivotal study that led to approval erlotinib in combination gemcitabine (Gemzar) advanced/metastatic chemonaive pancreatic patients. The demonstrated statistically significant increase overall survival accompanied an toxicity. Physicians now have new option adenocarcinoma pancreas.
cancernetwork.com参考文章(10)
De-Rong Xie, Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone World Journal of Gastroenterology. ,vol. 12, pp. 6973- 6981 ,(2006) , 10.3748/WJG.V12.I43.6973
H A Burris, M J Moore, J Andersen, M R Green, M L Rothenberg, M R Modiano, M C Cripps, R K Portenoy, A M Storniolo, P Tarassoff, R Nelson, F A Dorr, C D Stephens, D D Von Hoff, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology. ,vol. 15, pp. 2403- 2413 ,(1997) , 10.1200/JCO.1997.15.6.2403
Frances A Shepherd, Second-line chemotherapy for non-small cell lung cancer. Expert Review of Anticancer Therapy. ,vol. 3, pp. 435- 442 ,(2003) , 10.1586/14737140.3.4.435
Roman Perez-Soler, The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clinical Cancer Research. ,vol. 10, ,(2004) , 10.1158/1078-0432.CCR-040017
John R. Johnson, Martin Cohen, Rajeshwari Sridhara, Yeh-Fong Chen, Gene M. Williams, John Duan, Jogarao Gobburu, Brian Booth, Kimberly Benson, John Leighton, Li Shan Hsieh, Nallalerumal Chidambaram, Paul Zimmerman, Richard Pazdur, Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clinical Cancer Research. ,vol. 11, pp. 6414- 6421 ,(2005) , 10.1158/1078-0432.CCR-05-0790
Michele Reni, Stefano Cordio, Carlo Milandri, Paolo Passoni, Elisa Bonetto, Cristina Oliani, Gabriele Luppi, Roberto Nicoletti, Laura Galli, Roberto Bordonaro, Alessandro Passardi, Alessandro Zerbi, Gianpaolo Balzano, Luca Aldrighetti, Carlo Staudacher, Eugenio Villa, Valerio Di Carlo, None, Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncology. ,vol. 6, pp. 369- 376 ,(2005) , 10.1016/S1470-2045(05)70175-3
M.L. Rothenberg, M.J. Moore, M.C. Cripps, J.S. Andersen, R.K. Portenoy, H.A. Burriss, M.R. Green, P.G. Tarassoff, T.D. Brown, E.S. Casper, A.-M. Storniolo, D.D. Von Hoff, A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Annals of Oncology. ,vol. 7, pp. 347- 353 ,(1996) , 10.1093/OXFORDJOURNALS.ANNONC.A010600
Frances A. Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour, Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 353, pp. 123- 132 ,(2005) , 10.1056/NEJMOA050753
Malcolm J. Moore, David Goldstein, John Hamm, Arie Figer, Joel R. Hecht, Steven Gallinger, Heather J. Au, Pawel Murawa, David Walde, Robert A. Wolff, Daniel Campos, Robert Lim, Keyue Ding, Gary Clark, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy Parulekar, Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology. ,vol. 25, pp. 1960- 1966 ,(2007) , 10.1200/JCO.2006.07.9525
Roy S. Herbst, Diane Prager, Robert Hermann, Lou Fehrenbacher, Bruce E. Johnson, Alan Sandler, Mark G. Kris, Hai T. Tran, Pam Klein, Xin Li, David Ramies, David H. Johnson, Vincent A. Miller, TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 23, pp. 5892- 5899 ,(2005) , 10.1200/JCO.2005.02.840